Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan
<h4>Background</h4> Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parki...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/?tool=EBI |
| _version_ | 1798031725658374144 |
|---|---|
| author | Nobutaka Hattori Atsushi Takeda Yuki Hanya Tadayuki Kitagawa Masaki Arai Yoshihiko Furusawa Hideki Mochizuki Masahiro Nagai Ryosuke Takahashi |
| author_facet | Nobutaka Hattori Atsushi Takeda Yuki Hanya Tadayuki Kitagawa Masaki Arai Yoshihiko Furusawa Hideki Mochizuki Masahiro Nagai Ryosuke Takahashi |
| author_sort | Nobutaka Hattori |
| collection | DOAJ |
| description | <h4>Background</h4> Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). <h4>Objective</h4> To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. <h4>Methods</h4> A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. <h4>Results</h4> In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). <h4>Conclusions</h4> The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living. |
| first_indexed | 2024-04-11T20:02:12Z |
| format | Article |
| id | doaj.art-2c6362786420438bbc73b3c4075c4161 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-11T20:02:12Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-2c6362786420438bbc73b3c4075c41612022-12-22T04:05:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01171Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in JapanNobutaka HattoriAtsushi TakedaYuki HanyaTadayuki KitagawaMasaki AraiYoshihiko FurusawaHideki MochizukiMasahiro NagaiRyosuke Takahashi<h4>Background</h4> Identifying the factors that influence health-related quality of life (HRQoL) is of great scientific interest, but a potential causal relationship between treatment and HRQoL has yet to be fully elucidated. Japanese patients reported better HRQoL outcomes on the Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain, a 6-question subset of the PDQ-39 which is considered to reflect the emotional aspects of the disease-specific HRQoL, when treated with rasagiline, than placebo, in both a monotherapy clinical trial (NCT02337725) and an adjunctive therapy clinical trial in patients with wearing-off phenomena (NCT02337738). <h4>Objective</h4> To investigate how rasagiline exerts its effect on the PDQ-39 emotional well-being domain in Japanese patients with Parkinson’s disease. <h4>Methods</h4> A path analysis was performed to assess the direct treatment effects of rasagiline on the PDQ-39 emotional well-being domain and the effects mediated indirectly through the influence on items related to motor symptoms by a post-hoc analysis of two clinical trials in Japan. <h4>Results</h4> In the monotherapy trial, the PDQ-39 emotional well-being domain was mainly affected indirectly through items related to motor symptoms (80.7%) composed of the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part II (67.2%) and Part III (13.5%). In the adjunctive therapy trial, the PDQ-39 emotional well-being domain was also mainly influenced indirectly through effects on items related to motor symptoms (1 mg/day: 54.7%, 0.5 mg/day: 57.6%) composed of MDS-UPDRS Part II (1 mg/day: 35.6%, 0.5 mg/day: 40.9%), Part III (1 mg/day: 8.0%, 0.5 mg/day: 8.3%) and mean daily OFF-time (1 mg/day: 11.1%, 0.5 mg/day: 8.4%). <h4>Conclusions</h4> The effects of rasagiline on the PDQ-39 emotional well-being domain were mediated primarily by influence on the subjective aspects of motor experiences of daily living.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/?tool=EBI |
| spellingShingle | Nobutaka Hattori Atsushi Takeda Yuki Hanya Tadayuki Kitagawa Masaki Arai Yoshihiko Furusawa Hideki Mochizuki Masahiro Nagai Ryosuke Takahashi Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan PLoS ONE |
| title | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
| title_full | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
| title_fullStr | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
| title_full_unstemmed | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
| title_short | Effects of rasagiline on Parkinson’s Disease Questionnaire (PDQ-39) emotional well-being domain in patients with Parkinson’s disease: A post-hoc analysis of clinical trials in Japan |
| title_sort | effects of rasagiline on parkinson s disease questionnaire pdq 39 emotional well being domain in patients with parkinson s disease a post hoc analysis of clinical trials in japan |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789184/?tool=EBI |
| work_keys_str_mv | AT nobutakahattori effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT atsushitakeda effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT yukihanya effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT tadayukikitagawa effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT masakiarai effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT yoshihikofurusawa effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT hidekimochizuki effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT masahironagai effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan AT ryosuketakahashi effectsofrasagilineonparkinsonsdiseasequestionnairepdq39emotionalwellbeingdomaininpatientswithparkinsonsdiseaseaposthocanalysisofclinicaltrialsinjapan |